Frankfurt - Delayed Quote EUR
Ultragenyx Pharmaceutical Inc. (UP0.F)
33.40
+1.20
+(3.73%)
At close: June 13 at 8:00:54 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 19 | 19 |
| Avg. Estimate | 161.67M | 164.17M | 649.82M | 835.73M |
| Low Estimate | 148M | 150M | 589M | 698.47M |
| High Estimate | 174M | 174.43M | 669.35M | 1.02B |
| Year Ago Sales | 147.03M | 139.49M | 560.23M | 649.82M |
| Sales Growth (year/est) | 9.96% | 17.69% | 15.99% | 28.61% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| UP0.F | -- | -- | -- | -- |
| S&P 500 | 13.13% | 2.41% | 7.55% | 14.06% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 10/22/2024 |
| Maintains | TD Cowen: Buy to Buy | 10/21/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 10/1/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 9/26/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/20/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/16/2024 |
Related Tickers
GXEA.F Galapagos NV
24.60
+0.82%
GLPG.VI Galapagos NV
24.92
+0.81%
38I.F Intellia Therapeutics, Inc.
6.79
-9.44%
4DN.MU Denali Therapeutics Inc.
12.91
-2.23%
2L9.F Blueprint Medicines Corporation
109.00
-0.91%
26CA.F ImmunityBio, Inc.
2.6460
-3.18%
2LB.F Iovance Biotherapeutics, Inc.
1.9322
+1.19%
MRUS Merus N.V.
54.61
-1.41%
VNDA Vanda Pharmaceuticals Inc.
4.5100
-2.59%
GOVX GeoVax Labs, Inc.
1.0300
-9.65%